The Swedish cleantech company Chromafora has acquired 100 percent of the shares in Montrose Environmental Group Denmark, a Danish specialist in per- and polyfluoroalkyl substances (PFAS) and provider of technical solutions for treating contaminated water. The acquisition is intended to broaden and strengthen Chromafora’s offering for PFAS treatment in complex water streams.
The transaction was completed on December 31, 2025, and involves the Danish subsidiary of Montrose Environmental Group, Inc. Following the acquisition, the company was renamed Chromafora Denmark ApS.
According to Chromafora, the acquisition adds technical expertise and operational capacity, particularly within PFAS treatment solutions designed for demanding field conditions.
Johan Seijmer, CEO of Chromafora, said: “We have strengthened Chromafora with key talent and expertise across multiple water treatment technologies. The acquisition expands market access and delivery capacity, aligns with our partner strategy, and accelerates growth by scaling a broader PFAS removal offering across the Nordic region and Europe.”
The acquisition is intended to broaden and strengthen Chromafora’s offering for PFAS treatment in complex water streams
The Danish team brings experience from a large installed base and established customer relationships, with solutions addressing regulatory requirements for long-chain PFAS. These capabilities are expected to complement Chromafora’s SELPAXT technology, which the company says is effective for short- and ultra-short-chain PFAS.
Tore Svendsen, Managing Director of Chromafora Denmark, commented: “We will continue to apply our knowledge and expertise in water treatment for customers across the Nordic region and the rest of Europe. With this acquisition, we now have greater strength, expertise, and capacity to further develop our services and solutions,” Svendsen said.
As part of the transaction, Montrose Environmental Group became an investor and shareholder in Chromafora. The companies stated that this marks the beginning of an expanded collaboration. In addition, ECT2, a subsidiary of Montrose, has entered into a licensing agreement with Chromafora for proprietary technology intended to support scaling and growth across Europe.
